Back to news

Why BridgeBio Pharma (BBIO) Stock Is Down Today

Investivoq PriceTracker

BridgeBio Pharma (BBIO) is down 5.8% today. Here is some analysis on what might have caused this price movement.

Analysis: The catalyst is not completely clear, but the move looks most consistent with profit-taking and continued digestion of prior share-supply news rather than a fresh negative fundamental update. That is because BridgeBio’s public commentary on September 23 was broadly upbeat, while investors are still balancing a rich valuation, multiple upcoming launches, and an August secondary sale by a large shareholder. ([investing.com](https://www.investing.com/news/transcripts/bridgebio-at-bernstein-healthcare-forum-fourproduct-growth-story-builds-93CH-4913424))

Details:

  • BBIO traded as low as $64.95 after opening at $69.23, a sharp intraday reversal from the prior close.
  • At a September 23 healthcare forum, management highlighted Attruby annualizing above $1 billion globally and framed BridgeBio as moving toward a four-product platform, which suggests the day’s decline was not driven by an obviously negative presentation. ([investing.com](https://www.investing.com/news/transcripts/bridgebio-at-bernstein-healthcare-forum-fourproduct-growth-story-builds-93CH-4913424))
  • BridgeBio’s August 10 quarterly update said all three planned NDAs had been submitted, including BBP-418 with a November 27, 2026 PDUFA date, while oral infigratinib had been submitted for achondroplasia. ([investor.bridgebio.com](https://investor.bridgebio.com/news/news-details/2026/BridgeBio-Reports-Second-Quarter-2026-Financial-Results-and-Corporate-Updates/default.aspx))
  • On August 14, BridgeBio disclosed the pricing of a secondary offering of 5,000,000 shares by KKR Genetic Disorder, which can leave an overhang even when company operations remain on track. This could still be weighing on sentiment. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1743881/000114036126033282/ef20080234_ex99-2.htm?utm_source=openai))

    • Sources:

    BridgeBio Pharma, SEC, Investing.com

    Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.

    $BBIO Insider Trading Activity

    BBIO Insider Trades

    $BBIO insiders have traded $BBIO stock on the open market 51 times in the past 6 months. Of those trades, 0 have been purchases and 51 have been sales.

    Here’s a breakdown of recent trading of $BBIO stock by insiders over the last 6 months:

    • JENNIFER E. COOK has made 0 purchases and 6 sales selling 278,192 shares for an estimated $21,920,434.
    • NEIL KUMAR (Chief Executive Officer) has made 0 purchases and 36 sales selling 241,083 shares for an estimated $17,612,688.
    • ANDREA ELLIS sold 17,167 shares for an estimated $1,442,028
    • RANDAL W. SCOTT has made 0 purchases and 4 sales selling 10,000 shares for an estimated $671,455.
    • HANNAH VALANTINE has made 0 purchases and 2 sales selling 5,004 shares for an estimated $341,523.
    • MARICEL APULI (Chief Accounting Officer) has made 0 purchases and 2 sales selling 4,000 shares for an estimated $303,280.

    To track insider transactions, check out Investivoq's insider trading dashboard. You can access data on insider stock transactions through the Investivoq API insider transaction endpoint.

    EARLY ACCESS
    Receive BBIO Data Alerts
    Real-time alerts on filings, insider trades, and market signals — before everyone else.
    Get Alerts →

    $BBIO Hedge Fund Activity

    We have seen 258 institutional investors add shares of $BBIO stock to their portfolio, and 259 decrease their positions in their most recent quarter.

    Here are some of the largest recent moves:

    • BLACKROCK, INC. removed 3,920,601 shares (-27.6%) from their portfolio in Q2 2026, for an estimated $292,006,362
    • WELLINGTON MANAGEMENT GROUP LLP added 2,824,971 shares (+113.7%) to their portfolio in Q2 2026, for an estimated $210,403,840
    • BROOKLANDS FUND MANAGEMENT LTD removed 2,750,000 shares (-100.0%) from their portfolio in Q1 2026, for an estimated $204,215,000
    • CITADEL ADVISORS LLC added 2,475,758 shares (+354.6%) to their portfolio in Q1 2026, for an estimated $183,849,789
    • JPMORGAN CHASE & CO added 2,397,995 shares (+inf%) to their portfolio in Q2 2026, for an estimated $178,602,667
    • PRICE T ROWE ASSOCIATES INC /MD/ removed 2,075,272 shares (-54.6%) from their portfolio in Q2 2026, for an estimated $154,566,258
    • FRAZIER LIFE SCIENCES MANAGEMENT, L.P. removed 1,900,000 shares (-55.1%) from their portfolio in Q2 2026, for an estimated $141,512,000

    To track hedge funds' stock portfolios, check out Investivoq's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Investivoq API 13F endpoint.

    $BBIO Congressional Stock Trading

    Members of Congress have traded $BBIO stock 2 times in the past 6 months. Of those trades, 2 have been purchases and 0 have been sales.

    Here’s a breakdown of recent trading of $BBIO stock by members of Congress over the last 6 months:

    • REPRESENTATIVE GILBERT RAY CISNEROS, JR. has traded it 2 times. They made 2 purchases worth up to $30,000 on 05/11, 04/29 and 0 sales.

    To track congressional stock trading, check out Investivoq's congressional trading dashboard. You can access data on congressional stock trades through the Investivoq API Congress trades endpoint.

    $BBIO Price Targets

    Multiple analysts have issued price targets for $BBIO recently. We have seen 8 analysts offer price targets for $BBIO in the last 6 months, with a median target of $101.0.

    Here are some recent targets:

    • Salim Syed from Mizuho set a target price of $96.0 on 06/16/2026
    • Whitney Ijem from Canaccord Genuity set a target price of $104.0 on 06/03/2026
    • Raghuram Selvaraju from HC Wainwright & Co. set a target price of $110.0 on 05/28/2026
    • Sean Laaman from Morgan Stanley set a target price of $98.0 on 05/28/2026
    • Eric Joseph from Citigroup set a target price of $82.0 on 05/19/2026
    • Cory Kasimov from Evercore ISI Group set a target price of $130.0 on 05/08/2026
    • Danielle Brill from Truist Securities set a target price of $102.0 on 04/29/2026

    This article is not financial advice. See Investivoq's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.